Berlin, Germany, 20 October 2017: How can HARMONY help patients suffering from hematologic malignancies (HMs) to gain access to the right treatment at the right time? The HARMONY Alliance was designed as a resourceful medicine offensive to battle neoplasms in hematology. Innovation is key in the design of breakthrough drugs, in easing the route for medicines to get from bench to bedside, and ultimately in finding the right treatment at the right time for HM patients.
During the General Assembly, partners and members will discuss challenges, lessons learned, and opportunities for research in HMs, especially in relation to multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-hodgkin’s lymphoma (NHL), myelodysplastic syndromes (MDS), and pediatric hematologic malignancies (HMs).
The keynote speaker is Alan List from the Moffit Cancer Center, who will elaborate on the initiatives taking place in Big Data and hemato-oncology in the United States. The two-day program will provide ample opportunity for networking and targeted meetings on specific issues, varying from data governance and analysis modelling to ethical considerations in relation to Big Data. The yield of ongoing work packages will be discussed and the roadmap for the second year of this five-year project will be defined.
HARMONY is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to enhance the development of better and safer medicines for patients. HARMONY is IMI's ace alliance in the HM area. Interested in starting a research project with big data analyses from HARMONY? Please contact the HARMONY Coordination Office at the Institute of Biomedical Research of Salamanca (IBSAL) at harmonyoffice@ibsal.es.
HARMONY: Providing the right treatment at the right time for HM patients
Harmony in Hematology
The Harmony Alliance consists of 51 partners and brings together key stakeholders from a broad spectrum of disciplines from 11 European countries. Expertise is drawn from academic institutions, national clinical disease networks, European organizations, patient advocacy groups, clinicians, and pharmaceutical companies, as well as regulatory agencies, experts in economics and ethics, and information and technology (ICT) specialists.
Download the press release in PDF
HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
